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• The EAS FHSC is an international initiative involving a network of investigators interested in FH from around 70 countries.• Information on FH prevalence is lacking in most countries; where available, data tend to align with contemporary estimates.• FH diagnosis and management varies widely across countries, with overall suboptimal identification and under-treatment.• In most countries diagnosis primarily relies on DLCN criteria, and less frequently on Simon Broom or MEDPED.• Therapy for FH is not universally reimbursed, and criteria vary across countries. Access to PCSK9i and apheresis is limited.
A R T I C L E I N F O
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A B S T R A C T
Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings
due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey
among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different
countries.
Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to
provide a brief report on FH status in their countries, including available information, programmes, initiatives,
and management.
Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available,
data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low
rates of FH detection are reported across all regions. National registries and education programmes to improve
FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis
primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic
testing is not widely implemented (frequent cost issues). There are only a few national official government
programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are
available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited.
Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall
suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and manage-
ment are underway, including development of national registries, but support, particularly from health autho-
rities, and better funding are greatly needed.
1. Introduction
Familial hypercholesterolaemia (FH) is a now major public health
concern [1,2]. Untreated FH confers a significantly higher and earlier
atherosclerotic cardiovascular disease (CVD) risk [1,3]. Furthermore,
contemporary studies suggest FH to be more common than previously
estimated [4]. Yet reports indicate it is still widely underdiagnosed and
under-treated [1]. Population characteristics, together with differences
in health systems and policies, clinical practice, resources, or available
information, among other factors, contribute to variations in FH iden-
tification and management across different sites and settings, and
countries.
The European Atherosclerosis Society FH Studies Collaboration
(EAS FHSC) is an international initiative which aims to develop a
worldwide, cross-regional registry of FH patients and promote a net-
work of investigators interested in FH (www.eas-society.org/fhsc). The
EAS FHSC protocol is described elsewhere [5]. Currently, investigators
from ∼70 countries are involved [6], with>10,000 cases already in-
cluded in the registry. Taking advantage of the wide network of FHSC
Lead Investigators (FHSC-LI), we conducted a survey to provide an
overview of FH status (prevalence/management/initiatives) in different
countries involved in the EAS FHSC.
2. Materials and methods
All FHSC-LI from countries formally involved in the EAS FHSC by
mid-May 2018 were invited by email to provide a brief report on FH
status in their countries. Specifically, FHSC-LI were asked about (1)
“Available information on FH in the country”; (2) “FH programmes and
initiatives”; (3) “FH management in the country”. Where more than one
FHSC-LI from the same country responded, a final joint report was
agreed. Methods are described in detail in the Supplementary Material.
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3. Results
73 of the 81 FHSC-LI responded to the survey, corresponding to 63
countries (from the overall 68 countries in the FHSC network at the
time of the study). Information is summarised by WHO region [7]
below and in Table 1 and Figs. 1–4.
3.1. AFRICA
3.1.1. Nigeria
The EAS-FHSC collaborative study is the first FH initiative in
Nigeria, established at University of Benin Teaching Hospital (UBTH).
After implementation at UBTH, it will be extended to other centres.
Dyslipidemias are managed by cardiology and endocrinology clinics.
Genetic testing is unavailable. The Centre for Disease Control of UBTH
operates a subsidised general population screening programme for a
variety of conditions including lipid testing, which will be used for
recruiting FH patients. Costs of care are mainly paid out-of-pocket,
while a few, mostly government workers, have health insurance. To
date, 7 patients have been diagnosed.
3.1.2. South Africa
The diverse ethnic profile and presence of founder effects among
selected groups (Afrikaners, Jews) make it difficult to accurately de-
termine the true FH prevalence. The estimated prevalence in the
Afrikaner population is among the highest worldwide (1:83) due to a
founder effect (3 founder mutations account for ∼90% of cases) [8].
The estimated prevalence in the South African Indian population is
∼1:100 but it is uncertain whether this is a true founder effect [9].
Information on prevalence in black South Africans remains limited
[10]; interestingly, the LDLR mutation c.137_142del (“CapeTown-1” or
“FH-Pedi-1”) was identified in several black Africans with a clinical FH
diagnosis and may be a common African mutation.
3.2. AMERICAS
3.2.1. Argentina
The FH Detection Program estimates a prevalence of 1:291 (Dutch
Lipid Clinics Network criteria [DLCN];> 100,000 cases expected).
Genetic testing is performed for individuals with DLCN>6; among
patients studied so far, 33% have mutations in LDLR (95%) and APOB
Fig. 1. FH-related initiatives in countries involved in the EAS FHSC network in the Africa and Eastern Mediterranean WHO regions.
In red, countries currently involved in the EAS FHSC network. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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(5%), 8 had homozygous FH (HoFH), and 4 mutations were novel
[11,12]. Cascade screening was performed in 22 families, clinically
and/or genetically. A polygenic risk score is used to assess polygenic
causes. FH care is reliant on individual physicians.
3.2.2. Brazil
The ELSA Study suggests heterozygous FH (HeFH) may affect 1:263
Brazilians (∼766,000 individuals). Currently, the only active genetic
cascade screening program in Brazil is Hipercol Brasil in Sao Paulo
(genetic testing for adults with low-density lipoprotein cholesterol
(LDL-C) ≥230mg/dL, to maximise cost-effectiveness), with 1719 het-
erozygotes, 25 homozygotes, 13 compound-heterozygotes and one
double-heterozygote identified by March 2018. To date, 4340 in-
dividuals from 440 families were screened. Genetic testing is funded by
a government tax reduction programme (PROADI-SUS), and cascade
screening by partnering between Samaritano Hospital and Heart
Institute (InCor) University of Sao Paulo. Most FH patients are under
non-specialist care and currently under-treated.
3.2.3. Canada
Estimated prevalence is 1:250 overall [13] (up to 1:80 in some areas
with founder effects [14]), with<10% of estimated cases identified.
FH Canada, a national registry, had included> 3100 FH patients by
December 2017. Diagnosis is made using the newly developed, sim-
plified Canadian FH definition, based on DLCN and Simon-Broome (SB)
criteria. Efforts are underway to develop clinically-approved assays for
genetic testing in several provinces. A free smartphone app is available
to impute baseline LDL-C and FH diagnosis using the Canadian defini-
tion, DLCN and SB [15]. Healthcare delivery for FH follows the Cana-
dian Clinical Practice Guidelines [16].
3.2.4. Chile
The 2010 National Health Survey detected 7 cases with LDL-C
≥230mg/dL from 1700 subjects with lipid measurements. Although
likely underestimating the true figure, available data suggest FH pre-
valence is 1:243 (> 69,000 cases [20–60 HoFH] in a 17,300,000 po-
pulation). A registry using clinical criteria and/or genetic diagnosis has
been developed in Santiago and Concepción (4 HoFH and 67 HeFH
registered so far). Draft Ministry of Health guidelines consider FH care
for the first time. Genetic testing and proprotein convertase subtilisin/
kexin type 9 inhibitors (PCSK9i) for severe FH have been proposed for
incorporation into national law regulations funding the cost of rare and
expensive diseases.
Fig. 2. FH-related initiatives in countries involved in the EAS FHSC network in the Americas WHO region.
In red, countries currently involved in the EAS FHSC network. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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3.2.5. Mexico
A national registry and non-government patient organisation have
been initiated to replace previous isolated initiatives. A large propor-
tion of FH cases are undiagnosed. Cases are treated mainly in reference
centres. Diagnosis is mostly clinical (genetic testing is only available in
referral centres). Accumulated data show that LDLR mutations (in-
cluding some novel) are the most frequent [12,17]. Currently each in-
stitution has its own FH model of care (no government-supported
programmes or national guidelines). The healthcare system does not
universally cover high-dose statins and ezetimibe and medications are
generally out-of-pocket expenses.
3.2.6. Uruguay
Estimated prevalence is ∼1:360 (∼9100 patients; 2.47% cases
identified to date) based on analysis of lipid profiles from a routine
clinical setting. In 2014, a Ministry of Health National Law and
Regulatory Decree established a National Program for Early Detection
and Treatment of FH (GENYCO). Suspected FH cases are selected in
reference clinics using software incorporating the DLCN criteria. The
Clinical Coordination Unit selects the index cases for genetic testing.
The registry currently includes 805 FH cases, 225 with positive mole-
cular diagnosis (68 index cases/139 relatives with LDLR or APOB mu-
tations and 18 index cases with positive polygenic FH score). FH
treatment is covered by the Integrated National Health System.
3.2.7. Venezuela
A prevalence of ∼1:300 was estimated from patients attending an
endocrinology unit in Ciudad Bolívar [18]. FH is diagnosed clinically
(previously, genetic diagnosis was also used in some patients) [19,20].
A major problem is the general shortage of medicines (including up to
85% of previously available drugs such as statins or ezetimibe) and lack
of PCSK9i or apheresis. This situation compromises the efforts to tackle
the FH burden and highlights the need for implementation of health
policies.
3.3. EASTERN MEDITERRANEAN
3.3.1. Arabian Gulf (Kuwait, Oman, Qatar, Saudi Arabia, United Arab
Emirates)
High consanguinity rate in the region (up to 50%) [21] suggests that
prevalence may be higher than that reported. Latest censuses suggest
∼130,693 HeFH and 87 HoFH cases. Only 57 mutations have been
reported in 17 Middle East and North Africa countries, attributed to the
lack of national registries and screening programmes [22]. A cross-
national Gulf FH-Registry initiated in February 2017. Although lipid
clinics and lipoprotein apheresis centres are available in the region, FH
remains under-treated. Only 13% of patients with acute coronary syn-
drome (ACS) achieve an LDL-C<70mg/dL (Gulf-COAST registry)
[23].
3.3.2. Egypt
Preliminary data from the Egyptian Cardiorisk project showed
premature atherosclerosis in 47% of men and 69% of women admitted
with ACS, of whom ∼50% may have HeFH [24,25]. A higher incidence
may occur in areas where consanguinity is common. The Egyptian FH
Research Forum is a national initiative aiming to empower the medical
Fig. 3. FH-related initiatives in countries involved in the EAS FHSC network in the WHO region of Europe (A–C).
In red, countries currently involved in the EAS FHSC network [138]. (For interpretation of the references to colour in this figure legend, the reader is referred to the
Web version of this article.)
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community and organisations to promote FH detection and manage-
ment to reduce the burden of premature atherosclerosis in Egypt.
3.3.3. Iran
FH awareness/knowledge are limited. An initiative to establish a
network of paediatric endocrinology experts in different referral centres
in Iran is planned. Currently, genetic testing has been performed in 32
probands (definite clinical FH) and first-degree relatives in collabora-
tion with MRL (Belgium) and UCL (UK), with diagnosis of 16 HoFH, 28
HeFH, and 1 compound HeFH. Most probands are children/adolescents
with LDLR mutations. There has been a call for identified cases to un-
dergo clinical, biochemical, echocardiographic and ophthalmological
examinations. Funding and personnel for the future development of this
project, cooperation with the global network, and access to novel
treatments, are needed.
3.3.4. Iraq
The first lipid clinic was established in February 2017 in Diwaniyah,
aiming to initiate the first lipid clinic network and FH Registry in Iraq.
Subsequent efforts led to opening 9 more clinics; participating physi-
cians attend specific training courses in Muscat, Oman. Genetic testing
is offered in the Sultan Qaboos Bin Saeed University Hospital, Oman.
Future plans involve improving quality of care and physician skills for
FH.
3.3.5. Lebanon
FH is particularly common (e.g. HoFH is 10-fold higher than in
other populations), attributable to founder effects and high con-
sanguinity rates [26,27]. The p.Cys681X mutation (“Lebanese allele”) is
responsible for FH in 81.5% of Lebanese probands from different re-
gions or religious communities [28]; We also showed that PCSK9 was a
modifier gene [28]. Other less frequent mutations in LDLR and
LDLRAP1 genes have also been reported [28,29]. The healthcare system
partially reimburses conventional FH treatment. The Ministry of Public
Health partially covers LDL-apheresis at the National LDL-Apheresis
Centre at a governmental Hospital. Genetic testing is available mainly
through research studies in universities.
3.4. EUROPE
3.4.1. Austria
HeFH/HoFH patients are thought to number ∼40,000/100 (only 15
HoFH identified so far). Genetic testing is available, but not routinely
reimbursed by the Austrian health system. There is no common rule as
to how FH patients are managed – partly by internists, endocrinologists,
cardiologists, paediatric lipid centres and general practitioners (GPs).
PCSK9i are generally only reimbursed in secondary prevention or with
proven statin intolerance.
3.4.2. Belgium
There are no quantitative estimates of HeFH prevalence; 9 HoFH
cases are identified to date. Negotiations for establishing a centralised
registry within the National Institute of Health (NIH) e-health platform
are ongoing. The FH management setting varies, including the few lipid
clinics. Genetic testing is covered by NIH and may be prescribed by any
clinicians, ideally for those with DLCN>5. Reimbursement for statin,
ezetimibe and PCSK9i is based on DLCN score. Lipoprotein apheresis is
only reimbursed through solidarity funding.
3.4.3. Bosnia and Herzegovina
Data are collected individually using DLCN and cascade screening
(no official national registry). Overall, ∼3%/11% of definite/probable
Fig. 3. (continued)
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FH cases have been identified, suggesting an estimated prevalence
of> 1:200. FH management is affected by lack of funding for labora-
tory and genetic testing, and under-treatment with the only available
therapy (statins). Significant steps towards raising FH awareness are
ongoing [30].
3.4.4. Bulgaria
EUROASPIRE-IV estimated a 9% age-standardised prevalence of
potential FH [31]. A study in 12 cardiology hospitals identified 196 FH
subjects (DLCN; 27 definite, 94 probable, 74 possible) from 24,000
subjects with ≥2 lipids measurements (2015–2016) [32]. Genetic
testing is paid by patients. Patients requiring combination therapy are
managed by lipid clinics, with 5% of very high- and 14.5% of high-risk
FH patients achieving LDL-C goals [32]. The health system reimburses
PCSK9i at 75% (if DLCN>6, on high-intensity statin, and LDL-
C> 3.6mmol/L if very-high risk,> 2.6mmol/L if multiple athero-
thrombotic events,> 5mmol/L for primary prevention); statins for
secondary prevention at 25%; and fixed atorvastatin-ezetimibe at 50%.
Since the programme started, 120 more patients are on PCSK9i.
3.4.5. Croatia
About 200 FH cases (MEDPED; one HoFH) are identified from the
estimated 15,000 (∼1% detection rate) [33]. A pilot regional screening
programme in ACS patients showed that 1:12 has possible FH. Genetic
testing will soon be available in a pilot project at the University of
Zagreb. Preliminary results suggest no FH patient achieved an LDL-
C<1.8mmol/L despite statin or statin/ezetimibe. FH patients are
managed in lipid clinics by lipid specialists, and also by cardiologists
and endocrinologists. PCSK9i are prescribed only in hospitals, covered
by the Croatian National Insurance (from hospitals own budgets).
3.4.6. Cyprus
There are no data on prevalence and no formal registry. Screening is
opportunistic at the discretion of the treating physician, who can refer
patients/relatives for genetic testing available centrally at a National
Institute. Studies have revealed clustering for LDLR mutations, possibly
due to low migration rates and high consanguinity [34]. Care is free for
those entitled to National Health Care (NHC). Most FH patients are
managed by cardiologists and internists, and treated with statins or
plasmapheresis (available in public hospitals) [35]; PCSK9i are be-
coming available privately and in the NHC (selected patients).
3.4.7. Czech Republic
Since joining the worldwide MEDPED initiative in 1998, a nation-
wide network of 69 centres has been established [36]. Currently, the
Czech National MEDPED Database includes 7784 FH patients (modified
MEDPED criteria; 19 HoFH) in 5884 families (19.5% of expected FH
patients in the Czech Republic, if prevalence is 1:250). Cascade
screening is facilitated using genetic testing. DNA samples are available
from 4963 unrelated patients (LDLR, APOB, and PCSK9 mutations were
Fig. 3. (continued)
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detected in 961, 488, and 1 patients, respectively). Statins/ezetimibe/
PCSK9i are fully reimbursed (PCSK9i restricted to secondary prevention
with LDL-C>3mmol/L, or HeFH with LDL-C> 4mmol/L, on max-
imum tolerated lipid modifying treatment [LMT]); LDL-apheresis is
fully reimbursed but restricted (few cases).
3.4.8. Denmark
HeFH prevalence is 1:223 clinically [37] or 1:217 genetically [38]
(Copenhagen General Population Study). A 2017 government report
concluded that, with a prevalence of 1:200–250, only 11–13% of
HeFH patients are identified (particularly lacking identification of
children). A 1:220 HeFH prevalence would translate to an allele fre-
quency of 1:440 and 1:193,600 HoFH frequency (expected 28 HoFH
individuals; very few already diagnosed). FH diagnosis/treatments
are covered by the healthcare system, including genetic testing where
needed.
3.4.9. Estonia
The North Estonia Medical Centre (NEMC) electronic database in-
cludes ∼1800 possible/probable/definite FH patients, suggesting a
prevalence of 1:440. An algorithm introduced to the NECM IT system
mandates DLCN scoring if LDL-C ≥5mmol/L (pure hypercholester-
olaemia) and informs on treatments according to individual scores.
Genetic testing is funded but used in limited cases. FH is mainly man-
aged by cardiologists in lipid clinics. Statins and ezetimibe are re-
imbursed, unlike PCSK9i, used only in a few patients; use of lipoprotein
apheresis is limited.
3.4.10. Finland
National guidelines for FH management are available, but there is
no national screening programme or registry. The mutation spectrum in
Finland is restricted and unique; 5 distinctive founder LDLR mutations
are identified, with a combined estimated heterozygous carrier rate of
1:500 [39,40]. If FH prevalence is ∼1:200, a substantial proportion of
Finnish FH is still molecularly undefined [1]. Up to 27,500 may have
FH, but, according to nationwide statistics, only ∼5000 patients re-
ceive reimbursement for LMT for hereditary dyslipidemia.
3.4.11. France
About 8000 FH patients are followed in lipid clinics (∼3.3% of the
expected 240,000 if prevalence is 1:250). In 2015, a national network
of physicians (mainly endocrinologists and cardiologists) and geneti-
cists created the national French FH Registry, sponsored by the
Nouvelle Société Francophone d’Athérosclérose (NSFA) [41]. Inclusion
is based on DLCN (probable diagnosis) and/or genetic mutation. By
March 2018, 4660 adults and children from 15 lipid clinics were in-
cluded throughout France, almost two-thirds with a genetic diagnosis
[42]. NSFA recommendations for FH management are guidelines for
standard practice in France [43]. PCSK9i are reimbursed (alirocumab
for HeFH with LDL-apheresis criteria; evolocumab for HoFH).
3.4.12. Germany
An estimated prevalence of 1:300 (HoFH: 1:860,000) [44,45] sug-
gests ∼275,000 individuals may have FH, but only a minority are di-
agnosed/treated. Genetic testing is available if indicated by the treating
physician, covered by statutory health insurance. Private health in-
surance is, however, reluctant to cover costs. There are no national FH
guidelines; patients are managed in primary care, internal medicine,
cardiology, and lipid clinics. The only systematic approach to collect
more information is the nationwide CaRe-High registry [46] (al-
ready> 500 individuals). CaRe-High also offers support for cascade
screening and cooperates with Cholco (German patient organisation).
PCSK9i and lipoprotein apheresis are available, covered by insurance.
3.4.13. Greece
The estimated prevalence is 1:250 (∼40,000 cases;> 90% remain
undiagnosed). Two university centres offer genetic testing, although
costs are met by patients. The national HELLAS FH Registry was re-
cently established [47]. Patients with LDL-C>190mg/dL (> 160mg/
dL in children) are evaluated for FH; if at least possible FH, they are
registered and offered cascade screening (genetic testing is free to se-
lected patients). FH is mainly managed in lipid clinics in large cities.
PCSK9i and lomitapide are offered free-of-charge to selected patients.
Three centres offer lipoprotein apheresis (reimbursed). Few patients
achieve LDL-C goals [48].
3.4.14. Hungary
FH may affect ∼20,000–40,000 individuals. The national network
involves 2 national centres (Budapest and Debrecen), and 18 regional
centres. The Hungarian FH-Registry includes 301 patients. The Registry
uses an automated programme that calculates the DLCN score; patients
with suspected FH are referred to regional centres. Genetic testing is
performed if needed (limited/partial funding). There are 2 LDL apher-
esis centres (Budapest, Debrecen); PCSK9i are available but not sub-
sidised.
3.4.15. Ireland
Studies suggest a decline in cholesterol levels in Ireland since the
1980s [49–51]. A recent study identified one possible FH case among
259 of the public screened [49]. A national FH database has been in-
itiated, supported by industry, which also funds lipid nurses for FH
screening. Cascade screening is offered [52]. Genetic testing became
available recently at St James Hospital (referrals based on DLCN score).
Patients receive treatment in different settings, particularly in cardi-
ology, diabetes and a small number (n= 5) of lipid clinics. Re-
imbursement for management of lipid disorders is currently unavail-
able. PCSK9i have been utilised only as part of an early access
programme which is now full.
3.4.16. Israel
FH research began> 20 years ago as part of the MEDPED initiative.
The estimated HeFH prevalence is 1:355 [53]. Currently ∼500 families
are followed; among 455 FH patients, 176 are mutation-positive, re-
presenting<5% of expected FH cases. The common mutations iden-
tified reflect the various ethnicities in the country (characteristic
founder effects identified in each ethnicity) [54,55]. 25 HoFH patients
were identified, reflecting a cultural tendency towards consanguinity.
Most patients are treated in lipid clinics; most> 40-year-old hyperch-
olesterolaemic patients are on statins; data in younger adults/children
and on LDL-C goal attainments in all age groups are lacking.
3.4.17. Italy
Data from Health Search IMS Health Longitudinal Patient Database
showed a prevalence (DLCN ≥6) of 1:526 [56]. Using only an LDL-C
cut-off of ≥250mg/dL identified 1:1038 and 1:369 among non-treated
and statin-treated subjects, respectively [57]. Among patients admitted
to rehabilitation and secondary prevention programmes, FH prevalence
was 1:27 [58]. Data from Sardinia and Sicily, two insular regions, re-
ported a 1:2500 rate of ARH1 mutation carriers (1:140,000 homo-
zygous) [59]. Patients are generally referred to lipid clinics [60]. Sub-
jects with suspected clinical FH undergo genetic testing (reimbursed by
the National Health Service [NHS]). Available treatments include li-
poprotein apheresis and PCSK9i, reimbursed under NHS specific mon-
itoring programme.
A.J. Vallejo-Vaz et al. Atherosclerosis 277 (2018) 234–255
244
3.4.18. Kyrgyzstan
There is a high cardiovascular morbidity rate. Earlier studies
showed that atherogenic lipid levels were lower in the Kyrgyz ethnic
group than in individuals of Caucasian descent. Although prevalence is
unknown, FH is thought to be more common than in other countries.
Genetic testing is unavailable. FH is managed by cardiologists and in-
ternists and treated with statins (not reimbursed). There are no accurate
data on LDL-C goal attainment.
3.4.19. Latvia
Prevalence is unknown but assumed at 1:250. There is no state
programme and few patients were diagnosed before the Latvian FH
Registry was established in 2015. To date, the Registry has identified
181 cases (2.3% of 7876 estimated HeFH cases; no HoFH). Cascade
screening is performed in first-degree relatives of index cases with
probable/definite FH. Genetic testing is not reimbursed but has been
funded by research grants for a few patients/relatives. About 5% of
patients had LDL-C at target before inclusion in the Registry [61].
Statins are reimbursed 50% in primary prevention; statins and ezeti-
mibe, 75–100% in secondary prevention; PCSK9i are available, but not
reimbursed.
3.4.20. Lithuania
Cardiovascular mortality rates are extremely high (56.1% in 2017).
With a population of 2,847,904, it is estimated that there are 14,240
(1:200) HeFH cases and 18 (1:160,000) HoFH cases. ∼15% of FH cases
are diagnosed. The nationwide Lithuanian High Cardiovascular Risk
primary prevention program [62,63], covered by the health system
since 2006, screens> 200,000 individuals every year; in> 93,000
middle-aged adults included in the electronic database for detailed
analysis, 3.2% had LDL-C ≥6mmol/L. High-risk patients with dysli-
pidaemia are managed in preventive cardiology units by cardiologists,
geneticists, apheresis specialists, and followed-up in primary care. Ge-
netic testing is reimbursed. Statins are reimbursed for primary/sec-
ondary prevention; PCSK9i are not reimbursed yet.
3.4.21. Malta
Up to 10% of the estimated 1500 FH individuals are identified. An FH
Registry started in 2017, run on a voluntary basis (no official funds);
inclusion has changed from opportunistic to cascade screening, with
relatives considered at lower cut-off LDL-C [64]. Genetic testing is un-
available. Patients are managed at the only national lipid clinic (or in-
ternal medicine clinics with the same physicians). FH patients are en-
titled to free treatment with statins, fibrates, and cholestyramine but
other therapies are not funded; PCSK9i are made available exceptionally.
96% of patients identified are on statins (60% at LDL-C goal).
3.4.22. Netherlands
Cascade screening was practised routinely between the early 1990s
and 2014 by StOEH, a government-subsidised foundation. Diagnosis
was based on the presence of mutations in LDLR/APOB/PCSK9. Genetic
analyses were performed by a core laboratory (Academic Medical
Centre, Amsterdam), while patient care was mostly at local lipid clinics.
Initially, only molecular diagnostics were performed in the screening
programme, with lipid testing included after the early 2000s. Based on
studies on HoFH prevalence and among primary care, a 1:200–250
HeFH prevalence is estimated (40% [∼30,000] patients identified)
[65–67].
3.4.23. Norway
Since 1991, the Unit for Cardiac and Cardiovascular Genetics (Oslo
University Hospital) performs all genetic testing and cascade screening
free-of-charge (government funded). Currently,> 8000 patients
(∼800 < 18 years; 13 HoFH) have been diagnosed. Estimated pre-
valence is 1:300, i.e. ∼17,000 cases. The National Advisory Unit on FH
was established in 2014. Diagnosis of index patients has increased
from<100 patients/year previously to> 350 patients/year in the last
2 years. There are 10 lipid clinics (largest in Oslo, with>1300 FH
patients seen every year). Few patients attain LDL-C goal with statins/
ezetimibe [68]. PCSK9i are available if LDL-C> 5mmol/L (> 4 mmol/
L if CVD) on statin/ezetimibe, or if eligible for apheresis.
3.4.24. Poland
Estimated prevalence is 1:250 (based on a meta-analysis of 6 ob-
servational studies) or 136,300 adults (only 2% diagnosed) [69,70].
Based on LIPIDOGRAM studies (2004–2015, ∼50,000 participants),
prevalence might be < 1:200 [71,72]. Five HoFH cases are described
[73,74]. Patients with DLCN ≥3 are referred for genetic testing, funded
by the National Health Program. The National Centre for FH at Uni-
versity Clinical Hospital, Medical University of Gdansk, was established
in 2017, financed by the Ministry of Health. From August 2017, 345
patients underwent genetic testing (153 positive, including 46 relatives;
1 HoFH). Since 1999, 1884 patients (562 families) have undergone
genetic testing and cascade diagnosis (data from the National Polish FH
Registry, Medical University of Gdansk, established in 2000). PCSK9i
are not reimbursed (under discussion with the Ministry of Health).
3.4.25. Portugal
There is no government programme for FH identification. However,
since 1999, the National Institute of Health "Dr Ricardo Jorge" pro-
moted the Portuguese FH Study [75]; to December 2017, 801 index
cases (clinical diagnosis) and>1000 relatives (cascade screening)
were referred, of whom 772 (319 index cases, 453 relatives, 11 HoFH)
had a potential pathogenic mutation. Establishment of a National FH
Registry is under discussion with the Ministry of Health. Statins and
ezetimibe (partly) and LDL-apheresis (fully) are covered by the health
system. Overall,< 10% of patients attain LDL-C goal.
3.4.26. Russia
The estimated number of HeFH patients is at least ∼590,000 (if
prevalence is 1:250 [13]). The Epidemiology of Cardiovascular Risk
Factors and Diseases Study in 2 Siberian regions reported prevalence for
definite/probable FH of 0.24%/0.68% [76]. Genetic testing is available
commercially but is used only in studies or paid by patients. FH care is
provided by cardiologists, and by lipid clinics in several large cities.
Ezetimibe and PCSK9i are commercially available but not reimbursed
by the health system. Apheresis is available in some large cities but is
not reimbursed. Few patients meet LDL-C goal [77]; in a study in 4 lipid
clinics (> 500 FH patients –DLCN ≥8 with coronary heart disease)
only 6.6% achieved an LDL-C< 1.8mmol/L [78].
3.4.27. Serbia
CVD is the leading cause of mortality (51.7%). 13.2% of the popu-
lation have hypercholesterolaemia [79,80]. There are no data on FH
prevalence and no national registry, but an active FH programme is in
place. Estimated FH prevalence is 1:500 (14,400–15,000 in>7 million
population). The only lipid unit (Clinical Centre of Serbia, Belgrade)
initiated a local registry based on opportunistic and cascade screening,
identifying> 700 FH patients (7 suspected HoFH). Genetic testing is
unavailable. Statins, ezetimibe and apheresis are reimbursed, but not
PCSK9i. Preliminary data suggest LDL-C goal attainment is low (statins
are frequently under-dosed).
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3.4.28. Slovakia
Estimated FH cases range from 10,858–21,716 (1:250–500 pre-
valence). Prevalence of the FDB_R3500Q mutation is 0.09% in the
general population [81]; 2 HoFH patients have been identified. The
MEDPED-Slovakia Registry collects information on identified FH pa-
tients (DLCN, SB, MEDPED) and includes 1184 probands from 2246
registered patients. Genetic testing availability is limited to research
grants and health insurance [82]. National paediatric cholesterol
screening (at 11 and 17 years) was initiated in 2004. Statins, ezetimibe
and PCSK9i are reimbursed by the health system.
3.4.29. Slovenia
One in 500 children born in 2008 have genetically confirmed HeFH
(3 HoFH) [83]. As mandated by law, total cholesterol is universally
screened at age 5 years [83]; those with elevated levels are referred to
UMC Ljubljana (UMCL) for genetic testing (funded by hospital funds/
research projects). Universal nationwide screening for CVD risk factors
is available in adults aged 35–70-years, with referral to lipid clinics if
FH is suspected (e.g. total cholesterol> 8.0mmol/L). FH children are
followed by paediatricians, adults at the UMCL lipid clinic. Statins/
ezetimibe are introduced from 8 to 10 years. Statins are fully re-
imbursed; ezetimibe is co-paid for primary prevention in adults; PCSK9i
are reimbursed for FH adults with LDL-C>5.0 mmol/L,> 4.0 mmol/L
or> 3.6mmol/L in primary prevention, secondary prevention or pro-
gressive CVD, respectively, on maximal statin/ezetimibe (or with
documented statin intolerance).
3.4.30. Spain
Although FH prevalence is estimated at 1:300 (> 150,000 subjects;
HoFH: 1:450,000) only ∼20% of cases have been detected (97 with
HoFH), 65% with clinical criteria and 35% with genetic testing (funded
by the NHS, indicated if the index case has DLCN ≥6) [84–86]. FH is
managed in lipid clinics and primary care. Lipoprotein apheresis,
PCSK9i and other LMT for FH are covered by the NHS. About 80% of FH
patients are on treatment; LDL-C goals are attained by 11% of adults
and 42% of children/adolescents [87,88]. A cardiovascular risk equa-
tion for FH developed from SAFEHEART might improve risk stratifi-
cation and indication for emerging treatments [89].
3.4.31. Switzerland
The highest worldwide prevalence of APOB pathogenic variants
(1:209) was discovered in Switzerland [90]. Along with LDLR-variants
(1:317), FH prevalence is 1:125–135. From the estimated 65,000 pa-
tients,> 1500 are listed in the nationwide Swiss FH Center (diagene
Research Institute). By 2018, available data suggest 0.8–3.3% of FH-
patients are diagnosed, similar to 1998 (2.3%) [91], highlighting the
need for the provision of additional resources to improve current de-
tection. The detection rate is considerably lower than the estimated
13% detection rate published in 2013 by others [1]. The discordance
between these estimates may have implications for resource allocation
and highlights the importance of the present Swiss initiative and the
FHSC to global health.
3.4.32. Turkey
A high prevalence (1:150–200; ∼420,000 cases) is expected due to
founder effects and high consanguinity (23%) [92,93]. EUROASPIRE-IV
suggested 8.9% of coronary patients have potential FH [31]. FH is
mainly diagnosed clinically due to the high cost of genetic testing.
Several registries are ongoing; A-HIT1, a nationwide survey of 88 HoFH
patients undergoing LDL-apheresis, showed that most experience in-
effective apheresis [94,95], and A-HIT2 (1000 FH adults from 30
clinics) showed that FH is undertreated even in specialized centres
(LDL-C goal attainment: 9.1%) [94]. A-HIT3 is in FH patients admitted
to coronary care units with premature MI. Statins, ezetimibe and
apheresis are reimbursed. PCSK9i are available (only evolocumab is
reimbursed for HoFH).
3.4.33. Ukraine
The prevalence of total cholesterol> 5mmol/L is 69.4% (LDL-
C>5mmol/L, 8.1%) [96], partly influenced by high rates of secondary
hypercholesterolaemia (13% hypothyroidism, 50% prediabetes/dia-
betes, 45.7% obesity). About 160,000 FH patients (∼0.4% of the po-
pulation) are expected (if prevalence is 1:250). There is no government
funding/support. Cascade screening is conducted. Genetic testing is
paid by patients (including 8 HoFH). Currently, the FHSC-related reg-
istry in Ukraine includes 165 patients (63% possible/20% probable/
17% definite FH). There are no specialized lipid clinics. FH care is co-
ordinated by the Dyslipidaemia Department, M.D. Strazhesko Institute
of Cardiology NAMS of Ukraine. State reimbursement for statins began
in 2018.
3.4.34. United Kingdom
Estimates suggest only 10–20% of HeFH cases are diagnosed (∼60
HoFH) [97]. LDLR/APOB/PCSK9 mutations are carried by ∼93%/5%/
2% of identified HeFH [98]. NICE 2017 updated guidelines recommend
SB or DLCN for diagnosis [99]. In 2008, NICE recommended DNA
testing to diagnose index cases, followed by family cascade testing.
Access to genetic testing remains limited, however, and few regions
have screening programmes supported by DNA testing. The imminent
re-design of Genomic Laboratory Service in England will improve ac-
cess to genetic testing. PCSK9i are commissioned by NHS (NICE tech-
nology appraisals 393/394). NHS England commissioned evolocumab
and lomitapide for HoFH.
3.4.35. Uzbekistan
Estimated prevalence is ∼160,000 HeFH/30 HoFH cases (based on
prevalence 1:200; 32.653 million population). FH identification is
based on target screening in outpatient departments and in the CAD and
Atherosclerosis Laboratory of the Republican Specialized Centre of
Cardiology (RSCC), Tashkent. Genetic testing is not routinely available
(since 2018, available in the Scientific Laboratory of Molecular Genetic
Studies). The RSCC database includes 105 HeFH (<0,01% of estimated
cases) and 3 HoFH (10%) patients. Patients are monitored by the RSCC
CAD and Atherosclerosis Laboratory. LDL-apheresis is available in pri-
vate clinics.
3.5. South-east Asia and western Pacific
3.5.1. Australia
HeFH prevalence is 1:250–350 [100,101]. A web-based registry
across Australia has included> 1000 subjects [102]. Cascade screening
from a local centrally coordinated clinical service has demonstrated
cost-effectiveness but requires nationwide implementation [103–105].
Screening in coronary care units is useful for detecting FH and elevated
lipoprotein(a) [106,107]. In primary care, electronic screening tools
can identify FH patients. FH is managed in lipid clinics, by cardiolo-
gists/endocrinologists, and in primary care according to a model of care
[108,109]. Lipoprotein apheresis for refractory FH with progressive
CHD is available, funded by the health system [109]. PCSK9i are re-
imbursed according to FH severity.
3.5.2. China
The reported FH prevalence is 0.28% (7.1% in premature MI)
[110,111]. On this basis, there could be 5.6 million HeFH and ∼5000
HoFH cases. Recent research showed that mean untreated LDL-C was
15.1 ± 3.8mmol/L in HoFH/compound HeFH, and 5.7 ± 1.3 in
HeFH [112]. Previously, DLCN was used widely and genetic testing was
self-funded. In 2018, an expert consensus group proposed diagnostic
criteria for Chinese FH [113]. There are few lipid clinics in China, and
widespread FH awareness is lacking, with many patients misdiagnosed/
under-treated. Only 4.2% definite/probable FH patients are treated
with high-intensity therapy [110] (statins/ezetimibe/probucol), cov-
ered by health insurance.
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3.5.3. Hong Kong
About 500 FH patients have been identified in 2 main centres (≤2%
of cases according to global data) [1]. Originally, MEDPED was used to
identify patients, with data presented at the second WHO Consultation
in Geneva (1998) [114]. More recently, DLCN was adopted after re-
commendation in recently developed local consensus guidance. FH
patients are usually managed in lipid/other specialist clinics in gov-
ernment hospitals. Statins/ezetimibe are generally provided at nominal
charge [115]. Plasmapheresis is used at Queen Mary Hospital for severe
cases.
3.5.4. India
There are no accurate data on FH prevalence [116]. A survey on FH
awareness in 79 GPs showed that 67% were unaware of FH definition
and 72% were unaware of FH prevalence [117]. An ongoing study in
Mumbai has enrolled 10/13/87 definite/probable/possible cases
(DLCN). Genetic screening for PCSK9 will use RT-PCR and sequencing.
Similar studies are being performed in South, North and East India
[118,119]. FH is treated in routine consultations at hospitals or private
clinics, but, due to the lack of lipid clinics, treatments rely on statins
only.
3.5.5. Japan
The estimated prevalence is 1:200–500 (1:160,000–1,000,000 for
HoFH). Clinical characteristics of HeFH/HoFH were reported by the
Research Committee of the Ministry of Health [120]. The Japanese
Atherosclerosis Society has published criteria for FH diagnosis in
adults/children [121–123]. Genetic testing is recommended for diag-
nosis (required for HoFH), but it is not yet covered by health insurance
and only available in several institutions. FH is managed by lipidolo-
gists/cardiologists/internists and primary care physicians. Health in-
surance covers 70% of medical costs for HeFH and 80% (up to a limit of
100$) for HoFH.
3.5.6. Malaysia
Estimated HeFH prevalence is ∼1:100 (∼0.4% identified) [124].
29 HoFH cases with LDLR mutations have been identified in 14 families
[124–127]. This research group has identified ∼707 clinical FH pa-
tients (190 screened for genetic mutations). Overall, 1524 cases have
been clinically diagnosed from various clinics and community; genetic
testing was performed in 1007 (43.9% with LDLR/APOB100/PCSK9
mutations) [124–130]. Genetic testing is not government-funded. FH is
managed in specialist lipid, endocrine and metabolic medicine, cardi-
ology, internal medicine and primary care clinics. Excluding PCSK9i
and apheresis, treatment is covered by the health system. Only 12.1% of
high-risk patients receive LMT (32.5% attain LDL-C goal) [131].
3.5.7. Singapore
There are an estimated 22,000 HeFH individuals among the ∼5.5
million population. The 2016 Ministry of Health Clinical Practice
Fig. 4. FH-related initiatives in countries involved in the EAS FHSC network in South-East Asia and Western Pacific WHO regions.
In red, countries currently involved in the EAS FHSC network 139. (For interpretation of the references to colour in this figure legend, the reader is referred to the
Web version of this article.)
A.J. Vallejo-Vaz et al. Atherosclerosis 277 (2018) 234–255
247
Guidelines recommended SB for clinical diagnosis [132]. Among 96
identified FH patients in one centre, 52% were heterozygous for LDLR
mutations and 4.2% heterozygous for APOB mutations [133]. The FH
programme in Singapore started in 2015, with proband identification
via opportunistic screening [133]. Cascade screening is challenging as
probands are reluctant to inform relatives. FH care is shared across
primary and tertiary care, public and private institutions. One single
centre study showed that only 57.7% of patients received LMT, and
56.3% attained goals (LDL-C< 1.8mmol/L or ≥50% reduction) [133].
3.5.8. Taiwan
Prevalence is estimated at 1:200–300. A national registry (Taiwan
FH Registry Study) was established in 2015 supported by the Taiwanese
Society of Lipids and Atherosclerosis, which published the “Taiwan
Lipid Guideline for High Risk Patients” in 2017 [134]. Four LDLR
mutations and one APOB mutation (among 136 reported) account for
34% of FH cases in Han Chinese population [135]. Genetic testing for
screening will be available from late 2018 at the National Taiwan
University Hospital (available for genetic diagnosis for Taiwan/other
countries). Recently, the Taiwan National Health Insurance approved
reimbursement of PCSK9i for HoFH.
3.5.9. Vietnam
The FH programme started in North Vietnam in 2014 using op-
portunistic screening to identify index cases, followed by cascade
screening. The social health insurance system partly covered the cost of
treatment. Currently, the registry includes 70 FH patients (DLCN and
age- and gender-specific LDL-C criteria) [64] (53 HeFH/8 HoFH ge-
netically confirmed). After diagnosis, only 15.7% of patients (6 HeFH, 5
HoFH) were regularly followed by cardiologists. LMT included statins
(100%), ezetimibe (36.4%), stanols (27.3%), and plasma exchange
(9.1%). 83.3% of HeFH cases had LDL-C< 2.5mmol/L. Mean LDL-C in
HoFH before and after treatment was 17.5 ± 6.0 and
10.2 ± 4.1mmol/L, respectively.
4. Discussion
This survey highlights the lack of information on FH prevalence in
most countries. Where available, data tend to agree with contemporary
estimates, higher than that traditionally considered [1]. In the absence
of data, the general reported figure of 1:250–500 [1] are frequently
assumed and extrapolated to local populations. There are, however,
several factors that influence FH identification/diagnosis and, thus,
estimation of the burden of disease. These include, among others: (i)
population characteristics, e.g. presence of different ethnicities, mi-
gration patterns, mutation spectrum (which may differ widely across
the world) [136], founder effects, consanguinity rate, and population
cholesterol levels (and factors that may influence them, e.g. dietary
patterns, lifestyle); (ii) general FH awareness among the community,
healthcare professionals and policy-makers [137]; (iii) socio-cultural
factors (e.g. disease visibility and social acceptance); (iv) lack of stan-
dardisation in diagnostic criteria and of adjustment to specific popu-
lation characteristics (e.g. the most widely used DLCN criteria use ab-
solute LDL-C levels as cut-offs, which may fit well with Western
populations with similar LDL-C frequency distribution like the Neth-
erlands; however in other regions or ethnicities or living standards
(even within the same countries, e.g. urban vs. rural) the 90th-95th
percentiles may vary considerably, and by using the Dutch cut-offs the
estimated or recorded FH prevalences may be over- or under-esti-
mated); (v) accessibility to genetic testing, or presence (and coverage)
of screening programmes; (vi) variability in clinical practice [4]. Con-
sideration of all these factors makes it difficult to accurately model FH
prevalence in a particular setting/population, and extrapolations be-
tween regions are likely inappropriate. Nevertheless, low rates of FH
identification are reported universally. To address this, national re-
gistries have been initiated in many countries, in some cases prompted
by participation in the EAS FHSC. Education programmes to improve
FH awareness and knowledge are a recognised priority. In most cases,
initiatives are promoted in association with scientific societies, aca-
demic/research institutions, and patient groups. Support and funding
for FH management and initiatives are often lacking.
In most countries, diagnosis primarily relies on DLCN, and less
frequently on SB or MEDPED. Whether these traditional criteria are
applicable to more contemporary populations and different regions is
uncertain. There is a need for country/region-specific tools for FH di-
agnosis (for the reasons discussed above, it is unlikely that a one-fits-all
standard, e.g. for LDL-C cut-off levels, be applicable to all populations,
but adjustments are likely needed); however, only a minority have re-
gionally-modified criteria. Though often available, genetic testing is not
widely implemented, with cost being a frequent issue (in some cases
self-funded or only available in the context of research). Where avail-
able, genetic testing is mainly used to confirm diagnosis where there is
a strong likelihood of FH based on clinical criteria. About one-third of
countries offer genetic cascade screening, albeit usually on a regional
basis with few offering nationwide coverage. Only a minority of “na-
tional government programmes” are promoted by health authorities.
FH management varies across (and frequently within) countries
(specialist lipid clinics, non-lipid specialists, and/or in primary care),
and under-treatment is common. High-intensity statins, usually with
add-on ezetimibe, are the standard of care. However, therapy for FH is
not universally reimbursed, and criteria vary across countries. In 4
countries ezetimibe is not available. PCSK9i are available in ∼two-
thirds of countries, but with restricted use. Lipoprotein apheresis is
offered in ∼60% of countries, usually limited to one centralised or a
few reference centres, sometimes in private healthcare.
In conclusion, this survey of> 60 countries participating in the EAS
FHSC reinforces the need to improve FH awareness, identification and
management worldwide. Registries (including data linkage studies),
both national and international, are essential for driving improvement
in FH care and policy. The EAS FHSC registry, which aims to generate
large-scale, cross-regional data on FH, will play a major role in this
respect.
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EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
investigators
National Lead Investigators for each country are identified as “NLI”.
FHSC COORDINATING CENTRE: Asif Akrami, Josip Cari, Martina
De Marcoi, Kausik K. Rayi, Christophe A.T. Stevensi, Antonio J. Vallejo-
Vazi; (i) Imperial College London, United Kingdom. ARGENTINA: Pablo
Corrali (NLI), Laura Schreierii; (i) FASTA University, School of Medicine,
Pharmacology Dept., Mar del Plata; (ii), University of Buenos Aires, Dept. of
Clinical Biochemistry, Laboratory of Lipids and Atherosclerosis, INFIB-
IOC-UBA, Buenos Aires. AUSTRALIA: Gerald F. Wattsi-iii (NLI), Jing
Pangi; (i) School of Medicine, Faculty of Health and Medical Sciences,
University of Western Australia, Perth; (ii) Lipid Disorders Clinic, Dept. of
Cardiology, Royal Perth Hospital; (iii) FH Australasia Network (FHAN).
AUSTRIA: Christoph J. Binderi (NLI), Hans Dieplingerii, Gabriele
Hanauer-Maderiii; (i) Dept. of Laboratory Medicine, Medical University of
Vienna; (ii) Division of Genetic Epidemiology, Dept. of Medical Genetics,
Clinical and Molecular Pharmacology, Innsbruck Medical University; (iii)
Project Coordinator FH Registry/Austrian Atherosclerosis Society.
BELGIUM: Olivier Descampsi (NLI), Johan Desutterii, Michel Langloisiii,
Ann Mertensiv, Ernst Rietzschelii, Caroline Wallemacqv; (i) Centres
Hospitaliers Jolimont, Haine Saint-Paul; (ii) UZ Gent; (iii) AZ Brugge; (iv)
UZ Leuven; (v) CHU Liège. BOSNIA AND HERZEGOVINA: Belma
Pojskici (NLI), Dzenana Isakovici, Amra M. Dzankovicii, Jasna
Obralijaiii, Lamija Pojskici, Ibrahim Sisici, Ena Stimjanini, Vildana A.
Torlaki; (i) Cantonal Hospital Zenica; (ii) Private Internal Medicine
Practice, Sarajevo; (iii) PI Health Center of Kakanj. BRAZIL: Raul D.
Santosi,ii (NLI), Cinthia E. Jannesi, Jose E. Kriegeri, Alexandre C.
Pereirai; (i) Heart Institute (InCor) University of Sao Paulo, Medical School
Hospital; (ii) Hospital Israelita Albert Einstein, Sao Paulo. BULGARIA:
Arman Postadzhiyan (NLI), Medical University of Sofia, President,
Bulgarian Society of Cardiology. CANADA: Jacques Genesti (NLI),
Isabelle Rueli,ii; (i) Research Institute of the McGill University Health
Center, Montreal, Quebec; (ii) FH Canada Registry Coordinator. CHILE:
Rodrigo Alonsoi (NLI), Sylvia Asenjoii, Ada Cuevasi; (i) Clínica Las
Condes, Santiago de Chile; (ii) Universidad de Concepción. CHINA: Jie Lini
(NLI), Lixin Jiangii (NLI); (i) Beijing Institute of Heart, Lung and Blood
Vessel Diseases; (ii) National Clinical Research Centre of Cardiovascular
Diseases, Fuwai Hospital, National Centre for Cardiovascular Diseases,
Beijing. CROATIA: Željko Reineri (NLI), Ivan Pećini; (i) University of
Zagreb, Zagreb School of Medicine, Dept. of Internal Medicine, Division of
Metabolic Diseases, University Hospital Center Zagreb. CYPRUS: Phivos
Symeonidesi (NLI), George Miltiadousii, Andrie G. Panayiotouii; (i)
Hippocrateon Private Hospital, Nicosia; (ii) Cyprus International Institute
for Environmental and Public Health, Cyprus University of Technology,
Limassol. CZECH REPUBLIC: Tomas Freibergeri,ii (NLI), Michal
Vrablikiii; (i) Centre for Cardiovascular Surgery and Transplantation, Brno;
(ii) Central European Institute of Technology, Masaryk University, Brno;
(iii) General University Hospital and First Faculty of Medicine, Charles
University, Prague. DENMARK: Børge G. Nordestgaardi,ii (NLI), Anne
Tybjærg-Hanseni-iii (NLI), Marianne Bennii,iii; (i) Dept. Clinical
Biochemistry and The Copenhagen General Population Study, Herlev and
Gentofte Hospital, Copenhagen University Hospital; (ii) Faculty of Health
and Medical Sciences, University of Copenhagen; (iii) Dept. Clinical
Biochemistry, Rigshospitalet, Copenhagen University Hospital. EGYPT:
Ashraf Reda (NLI), Menofia University, President of the Egyptian
Association of Vernacular Biology and Atherosclerosis (EAVA). ESTONIA:
Margus Viigimaai (NLI), Silver Heinsarii; (i) Centre for Cardiovascular
Medicine, North Estonia Medical Centre, Tallinn University of Technology;
(ii) North Estonia Medical Centre, Tallinn University of Technology.
FINLAND: Elisabeth Widén (NLI), Institute for Molecular Medicine
Finland FIMM, University of Helsinki. FRANCE: Eric Bruckerti (NLI), S.
Béliardii; (i) Dept. of Endocrinology, Institut E3M et IHU
cardiométabolique, Hôpital Pitié Salpêtrière, Paris; (ii) Dept. of
Endocrinology, APHM, Aix Marseille Univ, INSERM, INRA, C2VN,
Marseille. GERMANY: Ulrich Laufsi (NLI), Winfried Märzii-v (NLI),
Heribert Schunkertvi (NLI), Ioanna Gouni-Bertholdvii, Wibke
Hengstenbergviii, Ulrich Juliusix, Ursula Kassnerx, Gerald Klosexi,
Christel Königxii, Wolfgang Königviii, Britta Ottexiii, Klaus Parhoferxiv,
Ulrike Schatzix, Nina Schmidtiv, Elisabeth Steinhagen-Thiessenx, Anja
Vogtxiv; (i) Klinik und Poliklinikfür Kardiologie, Universitäts klinikum
Leipzig; (ii) Medizinische Klinik V (Nephrologie, Hypertensiologie,
Rheumatologie, Endokrinologie, Diabetologie), Medizinische Fakultät
Mannheim der Universität Heidelberg, Mannheim; (iii) Synlab Akademie,
Synlab Holding Deutschland GmbH, Mannheim und Augsburg; (iv) D-A-CH-
Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e.V., Hamburg;
(v) KlinischesInstitutfür Medizinische und Chemische Labordiagnostik,
Medizinische Universität Graz, Graz, Austria; (vi) Deutsches Herzzentrum
München, Technische Universität München, Deutsches Zentrumfür Herz-und
Kreislauferkrankungen (DZHK), Munich Heart Alliance; (vii) Center for
Endocrinology, Diabetes, and Preventive Medicine, University of Cologne;
(viii) Deutsches Herzzentrum, Munich; (ix) Dept. of Internal Medicine III,
University Hospital Carl Gustav Carus at the Technische Universität
Dresden; (x) Center for Internal Medicine with Gastroenterology and
Nephrology, Lipid Clinic, Charité Berlin; (xi) Joint Practice for Internal
Medicine, Gastroenterology and Cardiology Beckenbauer & Maierhof,
Bremen; (xii) Clinic of Internal Medicine, Lipid Clinic, Klinikum Links der
Weser, Bremen; (xiii) Medical Clinic D, Lipid Clinic, University Hospital
Münster; (xiv) Medical Clinic and Policlinic IV, Ludwig-Maximilian
University, Munich. GREECE: Evangelos Liberopoulosi (NLI), Alexandros
D. Tselepisii (NLI), Christina Antzaiii, Vasilios Athyrosiii, Eleni
Bilianouiv, Amalia Boufidouv, George Chrousosvi, Moses Elisafi,
Anastasia Garoufivii, Niki Katsikiviii, Genovefa Kolovouix, Vasilios
Kotsisiii, Loukianos Rallidisx, Christos Rizosi, Emmanouel Skalidisxi,
Ioannis Skoumasxii, Kostantinos Tziomalosxiii; (i) Faculty of Medicine,
University of Ioannina; (ii) Atherothrombosis Research Centre, University of
Ioannina; (iii) Dept. of Internal Medicine, Aristotle University of
Thessaloniki Medical School, Papageorgiou Hospital, Thessaloniki; (iv)
Dept. of Cardiology, Tzaneio Hospital, Athens; (v) Dept. of Cardiology,
AHEPA Hospital, Thessaloniki; (vi) First Dept. of Pediatrics, National and
Kapodistrian University of Athens Medical School, St. Sophia Children
Hospital, Athens; (vii) Second Dept. of Pediatrics, Medical School, National
& Kapodistrian University of Athens, “P & A Kyriakou” Children's Hospital;
(viii) Dept. of Internal Medicine, Aristotle University of Thessaloniki Medical
School, Hippokrateion Hospital, Thessaloniki; (ix) Dept. of Cardiology,
Onassis Cardiac Surgery Centre, Athens; (x) Dept. of Cardiology, University
of Athens Medical School, Attiko University Hospital, Athens; (xi) Dept. of
Cardiology, University Hospital of Herakleion; (xii) Dept. of Cardiology,
Hippokrateion Hospital, Athens; (xiii) First Propedeutic Dept. of Internal
Medicine, Aristotle University of Thessaloniki Medical School, AHEPA
Hospital, Thessaloniki. HONG KONG: Brian Tomlinson (NLI), Dept. of
Medicine and Therapeutics, The Chinese University of Hong Kong.
HUNGARY: György Paragh (NLI), Dept. of Internal Medicine, University
of Debrecen Faculty of Medicine, Debrecen. INDIA: Tester F. Ashavaidi
(NLI), J.P.S. Shawneyii; (i) P. D Hinduja National Hospital and Medical
Research Centre, Mumbai; (ii) Sir Ganga Ram Hospital, Delhi. IRAN:
Amirhossein Sahebkari-iii (NLI), Mohammad R. Abbaszadeganiv, Majid
Aminzadehv, Sousan Hosseiniiv, Moein Mobinivi, Rahim Vakiliiv,vii,
Hossein Zaeriviii; (i) Biotechnology Research Center, Pharmaceutical
Technology Institute, Mashhad University of Medical Sciences; (ii)
Neurogenic Inflammation Research Center, Mashhad University of Medical
Sciences; (iii) School of Pharmacy, Mashhad University of Medical Sciences;
(iv) Medical Genetics Research Center, Mashhad University of Medical
Sciences; (v) Diabetes Research Center, Ahvaz Jundishapur University of
Medical Sciences, Ahvaz; (vi) School of Medicine, Mashhad University of
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Medical Sciences; (vii) Dept. of Paediatric Endocrinology and Metabolism,
Faculty of Medicine, Mashhad University of Medical Sciences; (viii)
Neonatal and Children Health Research Centre, Golestan University of
Medical Sciences, Gorgan. IRAQ: Mutaz Al-khnifsawi (NLI), Al-Qadisiyah
University, Faculty of Medicine, Dept. of Internal Medicine, Diwaniya City.
IRELAND: Vincent Maheri (NLI), Ruth Agari, Gerard Boranii, Nial
Colwelliii, Vivion Crowleyiv, Maeve Durkinv, Damian Griffinvi, Michael
Kellyii, Ana Rakovac-Tisdalliv; (i) Advanced Lipid Management and
Research (ALMAR) Centre, Dublin; (ii) Tallaght University Hospital,
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